Should all patients with suspected coronary artery disease undergo coronary angiography with 16-row MDCT?
Daniel A Herzka and Ahmed M Gharib*
Correspondence *Clinical Research Center, National Institutes of Health, Room 3–5340, Building 10, MSC 1263, 10 Center Drive, Bethesda, MD 20892, USA
Email agharib@nhlbi.nih.gov
This article has no abstract so we have provided the first paragraph of the full text.
Recent technological advances have made MDCT a potentially practical tool for the assessment of CAS. The relative 'ease of use' of this imaging modality could render it a replacement or complement to other noninvasive techniques, such as stress radionuclide scans and echocardiography, used for the evaluation of CAD. Current strategies propose including MDCT angiography in the assessment of patients with intermediate likelihood of CAD.1 The question remains, however, as to whether this technology has progressed sufficiently to be incorporated into standard risk-assessment pathways.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
